Ani Pharmaceuticals (ANIP) Current Deferred Revenue (2012 - 2022)

Ani Pharmaceuticals has disclosed Current Deferred Revenue across 8 years of filings, most recently posting $116000.0 for Q1 2022.

• Current Deferred Revenue for Q1 2022 came in at $116000.0, up 87.1% year-over-year; the trailing twelve-month figure through Mar 2022 was $116000.0 (up 87.1% YoY), and the FY2021 annual result was $87000.0, up 8.75% from the prior year.
• Current Deferred Revenue came in at $116000.0 for Q1 2022 at Ani Pharmaceuticals, up from $87000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $735000.0 in Q3 2018 to a low of $62000.0 in Q1 2021.
• The 5-year median for Current Deferred Revenue is $116000.0 (2022), against an average of $304133.3.
• Across the five-year window, Current Deferred Revenue slumped 82.26% in 2020 and jumped 87.1% in 2022, its largest moves.
• Ani Pharmaceuticals' Current Deferred Revenue stood at $711000.0 in 2018, then sank by 36.57% to $451000.0 in 2019, then plunged by 82.26% to $80000.0 in 2020, then grew by 8.75% to $87000.0 in 2021, then surged by 33.33% to $116000.0 in 2022.
• The last three Current Deferred Revenue figures came in at $116000.0 (Q1 2022), $87000.0 (Q4 2021), and $62000.0 (Q3 2021), per Business Quant data.